



## **FOR IMMEDIATE RELEASE**

### **CONTACT**

Jeff Price, Marketing Manager, HOPA  
847.375.4717 | [jprice@hoparx.org](mailto:jprice@hoparx.org)

### **Jeremy Whalen, PharmD BCOP, New At-Large Member for 2018-2019 Term**

Chicago, IL (March 21, 2018): Jeremy Whalen, PharmD BCOP, took office as an at Large Member of the Board of Directors of Hematology/Oncology Pharmacy Association (HOPA) at the recent 14th HOPA Annual Conference in March. Dr. Whalen has been an active member of HOPA since 2008 and has been fortunate to pursue his passion in developing and delivering contemporary, quality oncology education within the organization. Dr. Whalen most recently served as a member of the Education Development Committee. Prior to that he was the chair of the Program Committee and has also been involved with the Session Proposal Taskforce and the Membership Committee.

Dr. Whalen is the Specialty Clinical Program Director of Oncology for Prime Therapeutics. In this role, he oversees oncology strategy and program development for pharmacy benefits and integration of medical drug benefits, affecting ~27 million covered lives. Prior to this career change, Dr. Whalen practiced for over 8 years managing North Memorial Health's Cancer Center in Robbinsdale, Minnesota. There he had clinical and operational responsibilities over both oncology infusion and retail services, financial patient advocates, Genetic Counselors, and the Tumor Registry program. Dr. Whalen was active in training both residents and students in ambulatory oncology and is a Clinical Assistant Professor for the Integrated Oncology Pharmacotherapy course at the University of Minnesota's College of Pharmacy. Dr. Whalen also co-founded and is the President of the Upper Midwest Oncology Education Network.

Dr. Whalen received his Doctorate of Pharmacy at Creighton University in Omaha, Nebraska. He then completed a PGY1 at Maine Medical Center in Portland, Maine, where both Dr. Alex Kappelman and Steve D'Amato fostered a passion for oncology pharmacy and introduced him to HOPA. Dr. Whalen was fortunate to then become the first PGY2 Oncology Specialty Resident at the University of Minnesota Medical Center in Minneapolis, Minnesota under Dr. Rebecca (Becky) Fahrenbruch, who remains a close mentor and inspired a commitment of service and advocacy for our profession. Dr. Whalen received his board certification in oncology pharmacy in 2010.

### **About HOPA**

Hematology/Oncology Pharmacy Association (HOPA) is a nonprofit, education-based organization formed in 2004 to help oncology and hematology pharmacy practitioners and their associates the best possible cancer care. HOPA supports research, provides education, encourages professional development and advocates for health policy issues that improve patient care. HOPA serves more than 2,700 members in the fields of oncology pharmacy, pharmacy



administration, and research, and includes pharmacy residents, interns, and technicians specializing in hematology/oncology practice.